CL2017003057A1 - Célula. - Google Patents

Célula.

Info

Publication number
CL2017003057A1
CL2017003057A1 CL2017003057A CL2017003057A CL2017003057A1 CL 2017003057 A1 CL2017003057 A1 CL 2017003057A1 CL 2017003057 A CL2017003057 A CL 2017003057A CL 2017003057 A CL2017003057 A CL 2017003057A CL 2017003057 A1 CL2017003057 A1 CL 2017003057A1
Authority
CL
Chile
Prior art keywords
protein
domain
joins
reason
phosphoriled
Prior art date
Application number
CL2017003057A
Other languages
English (en)
Spanish (es)
Inventor
Martin Pulé
Khai Kong
Shaun Cordoba
Simon Thomas
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of CL2017003057A1 publication Critical patent/CL2017003057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CL2017003057A 2015-06-01 2017-11-30 Célula. CL2017003057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1509413.9A GB201509413D0 (en) 2015-06-01 2015-06-01 Fusion protein

Publications (1)

Publication Number Publication Date
CL2017003057A1 true CL2017003057A1 (es) 2018-03-16

Family

ID=53677545

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003057A CL2017003057A1 (es) 2015-06-01 2017-11-30 Célula.

Country Status (20)

Country Link
US (2) US11345734B2 (enExample)
EP (2) EP3730609A1 (enExample)
JP (4) JP6833727B2 (enExample)
KR (1) KR102275460B1 (enExample)
CN (1) CN107667170B (enExample)
AU (1) AU2016272457B2 (enExample)
BR (1) BR112017023190A2 (enExample)
CA (1) CA2986956C (enExample)
CL (1) CL2017003057A1 (enExample)
DK (1) DK3303568T3 (enExample)
ES (1) ES2791338T3 (enExample)
GB (1) GB201509413D0 (enExample)
HU (1) HUE050132T2 (enExample)
IL (1) IL255594B (enExample)
MX (1) MX383118B (enExample)
PL (1) PL3303568T3 (enExample)
PT (1) PT3303568T (enExample)
RU (1) RU2729158C2 (enExample)
WO (1) WO2016193696A1 (enExample)
ZA (1) ZA201707334B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
JP7032304B2 (ja) 2015-07-28 2022-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用
JP7012645B2 (ja) * 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
WO2017123559A2 (en) 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
GB201620070D0 (en) * 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201621889D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Cell
EP3585394A4 (en) * 2017-02-23 2021-06-30 Olema Pharmaceuticals, Inc. COMPOSITIONS AND PROCEDURES FOR REGULATING IMMUNE SYSTEM ACTIVITY
WO2018160731A1 (en) * 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
WO2018211244A1 (en) * 2017-05-15 2018-11-22 Autolus Limited A cell comprising a chimeric antigen receptor (car)
JP7414714B2 (ja) * 2017-09-29 2024-01-16 ナショナル ヘルス リサーチ インスティテューツ 抗腫瘍および抗ウイルスｔ細胞の生存および機能性を増強する方法および組成物
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) * 2017-10-25 2017-12-06 Autolus Ltd Vectors
WO2019118518A2 (en) * 2017-12-11 2019-06-20 Senti Biosciences, Inc. Inducible cell receptors for cell-based therapeutics
US20210363217A1 (en) * 2018-06-19 2021-11-25 Autolus Limited Cell
CN109294982B (zh) * 2018-09-30 2020-11-06 北京鼎成肽源生物技术有限公司 一种rff2细胞
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CA3121911A1 (en) * 2018-12-06 2020-06-11 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
GB201820157D0 (en) * 2018-12-11 2019-01-23 Imperial Innovations Ltd Method of treatment
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
ES3051182T3 (en) 2019-01-23 2025-12-26 Miltenyi Biotec Bv & Co Kg A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
CN113710697A (zh) * 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
MA55896A (fr) * 2019-05-07 2022-03-16 Modernatx Inc Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser
CN118165120A (zh) * 2019-07-22 2024-06-11 南京助天中科科技发展有限公司 一种嵌合抗原受体及其应用
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US20220401537A1 (en) * 2019-09-16 2022-12-22 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
IL292387B2 (en) * 2019-10-23 2025-08-01 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Chimeric polypeptide for regulating immune cells
US20220389075A1 (en) * 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021119489A1 (en) * 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
CN115066249A (zh) 2020-02-04 2022-09-16 美天施生物科技有限两合公司 表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
AU2021297458B2 (en) * 2020-06-25 2026-06-18 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
US11433100B2 (en) 2020-08-20 2022-09-06 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
US20250019740A1 (en) * 2020-10-26 2025-01-16 Board Of Regents, The University Of Texas System Mutant proteases and uses thereof
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
CN114807042B (zh) * 2021-01-22 2024-09-03 南京助天中科科技发展有限公司 一种嵌合抗原受体改造的nk细胞及其制备方法与应用
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
JP2023008482A (ja) 2021-07-06 2023-01-19 日本たばこ産業株式会社 たばこ製品の香味料担持構成部材及びこの製造方法
WO2023044304A1 (en) * 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
EP4426341A4 (en) * 2021-11-04 2025-10-01 Dana Farber Cancer Inst Inc DEVELOPMENT OF INDUCIBLE CHIMERIC CLUSTERED ANTIGEN RECEPTOR (CCAR) CONSTRUCTS
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
CN119331105B (zh) * 2024-09-03 2025-10-28 中国人民解放军空军军医大学 靶向多种免疫检查点的通用多肽-protac及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
EP0831875A4 (en) * 1995-06-07 2002-07-31 Univ Pennsylvania METHODS OF INHIBITING PHAGOCYTOSIS
JP2000506007A (ja) * 1996-02-23 2000-05-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 細胞によるアッセイ
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
US7060506B2 (en) 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
CN102070719A (zh) * 2010-11-24 2011-05-25 中国人民解放军第四军医大学 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47
AU2014386824B2 (en) * 2013-03-15 2019-05-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
EP3858379A1 (en) 2013-11-21 2021-08-04 Autolus Limited Cell
RS63601B1 (sr) * 2014-10-09 2022-10-31 Univ Yamaguchi Vektor ekspresije car i t ćelije koje eksprimiraju car
GB201620070D0 (en) 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201717524D0 (en) * 2017-10-25 2017-12-06 Autolus Ltd Vectors
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB202007044D0 (en) * 2020-05-13 2020-06-24 Autolus Ltd Method

Also Published As

Publication number Publication date
EP3303568A1 (en) 2018-04-11
IL255594B (en) 2020-11-30
CN107667170B (zh) 2021-09-03
NZ737662A (en) 2021-10-29
ES2791338T3 (es) 2020-11-03
RU2017145074A3 (enExample) 2019-07-17
US11345734B2 (en) 2022-05-31
CN107667170A (zh) 2018-02-06
JP2022066380A (ja) 2022-04-28
HK1246825A1 (en) 2018-09-14
IL255594A (en) 2018-01-31
AU2016272457A1 (en) 2017-12-14
PT3303568T (pt) 2020-06-08
BR112017023190A2 (pt) 2018-07-17
CA2986956A1 (en) 2016-12-08
JP2018517410A (ja) 2018-07-05
CA2986956C (en) 2022-03-22
US20220267404A1 (en) 2022-08-25
EP3303568B1 (en) 2020-05-06
KR20180012762A (ko) 2018-02-06
JP2020115898A (ja) 2020-08-06
JP2024149818A (ja) 2024-10-18
RU2017145074A (ru) 2019-07-09
US12612443B2 (en) 2026-04-28
HUE050132T2 (hu) 2020-11-30
KR102275460B1 (ko) 2021-07-14
EP3730609A1 (en) 2020-10-28
US20190023761A1 (en) 2019-01-24
JP6833727B2 (ja) 2021-02-24
DK3303568T3 (da) 2020-07-06
RU2729158C2 (ru) 2020-08-04
ZA201707334B (en) 2020-02-26
WO2016193696A1 (en) 2016-12-08
MX383118B (es) 2025-03-13
AU2016272457B2 (en) 2020-12-10
GB201509413D0 (en) 2015-07-15
MX2017014630A (es) 2018-06-06
PL3303568T3 (pl) 2020-11-02

Similar Documents

Publication Publication Date Title
MX2017014630A (es) Celula.
ZA202401297B (en) Anti-tigit antibodies and methods of use
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
EA201792042A1 (ru) T-клетка, которая экспрессирует t-клеточный рецептор (tcr) гамма-дельта и химерный антигенный рецептор (car)
CL2018000042A1 (es) Anticuerpos de unión a tau
BR112018009129A2 (pt) receptores de antígeno quimérico que visam her2
CL2018000043A1 (es) Anticuerpos de unión a tau
MX2017003596A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
CU24475B1 (es) Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1
MX2018004721A (es) Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
CU20190099A7 (es) Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo
MX2024007711A (es) Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
CL2017002413A1 (es) Receptor antigénico quimérico
MX2017006233A (es) Celula.
CL2018000415A1 (es) Receptor quimerica de citocinas.
MX2020003132A (es) Anticuerpos anti-ctla4 y usos de los mismos.
ECSP19018327A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
NZ728674A (en) Signalling system
CL2017003246A1 (es) Anticuerpo
CL2017001292A1 (es) 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
AR114112A1 (es) Anticuerpos de glipicano 3 y conjugados de los mismos
AR121189A2 (es) Anticuerpos anti-tigit y métodos de uso
CL2018002268S1 (es) Foco delantero de vehículo.